Inhibition of GPX4 enhances CDK4/6 inhibitor activity in breast cancer

被引：0
|
作者：
Abreu, Maria Teresa Herrera
Khalid, Uzma
Ning, Jian
Cutts, Rosalind
Wilson, Gemma
Lord, Christopher
Swain, Amanda
Turner, Nicholas
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PS12-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS12-04
引用
收藏
页数：2
相关论文
共 50 条
  • [31] CDK4/6 inhibition in breast cancer: current practice and future directions
    Pernas, Sonia
    Tolaney, Sara M.
    Winer, Eric P.
    Goel, Shom
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [32] Anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells
    Kishino, E.
    Ogata, R.
    Saitoh, W.
    Koike, Y.
    Ohta, Y.
    Kanomata, N.
    Moriya, T.
    Kurebayashi, J.
    BREAST, 2019, 44 : S28 - S28
  • [33] Update on CDK4/6 Inhibitors in Breast Cancer
    Tolaney, Sara M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (06) : 298 - 300
  • [34] The Role of CDK4/6 Inhibitors in Breast Cancer
    Murphy, Conleth G.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (06)
  • [35] The Role of CDK4/6 Inhibitors in Breast Cancer
    Conleth G. Murphy
    Current Treatment Options in Oncology, 2019, 20
  • [36] CDK4/6 inhibitors in luminal breast cancer
    Gnant, Michael
    Steger, Guenther G.
    Bartsch, Rupert
    LANCET ONCOLOGY, 2015, 16 (01): : 2 - 3
  • [37] Preclinical head-to-head comparison of CDK4/6 inhibitor activity toward CDK4 vs CDK6
    Delach, Scott
    Caponigro, Giordano
    CANCER RESEARCH, 2021, 81 (04)
  • [38] The transcriptome of CDK4/6 inhibition
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    AGING-US, 2017, 9 (08): : 1859 - 1860
  • [39] Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer.
    Liu, Renyan
    Pantelidou, Constantia
    Jadhav, Heta
    Shapiro, Geoffrey
    CANCER RESEARCH, 2022, 82 (12)
  • [40] The Effects of HER2 on CDK4/6 Activity in Breast Cancer
    Sinclair, William D.
    Cui, Xiaoyan
    CLINICAL BREAST CANCER, 2022, 22 (03) : E278 - E285
12345